Form 4: Amicus Therapeutics Director Margaret McGlynn Boosts Stake with Significant Equity Grants

Amicus Therapeutics Director Margaret G. McGlynn received grants of 20,414 Restricted Stock Units and 74,872 stock options on June 5, 2025, increasing her beneficial ownership in the company.

Summary

• On June 5, 2025, Margaret G. McGlynn, a Director of Amicus Therapeutics, Inc. (FOLD), was granted 20,414 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0.0 per share and will vest in full on the one-year anniversary of the grant date, payable in common stock.
• Following this transaction, Ms. McGlynn beneficially owns 91,550 shares of Common Stock.
• Additionally, on the same date, Ms. McGlynn was granted 74,872 stock options with an exercise price of $5.96 per share.
• These stock options will vest 100% on the one-year anniversary of the grant date and have an expiration date of June 5, 2035.
• After this transaction, Ms. McGlynn beneficially owns 74,872 stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a standard and beneficial practice of aligning director interests with shareholder value through equity compensation. It indicates continued commitment from a key board member.

Positives

• The grant of equity compensation to a director aligns their interests with those of the shareholders, encouraging long-term commitment and performance.
• The increase in beneficial ownership by a director can be seen as a vote of confidence in the company's future prospects.

Future Outlook

The granted Restricted Stock Units and stock options are scheduled to vest in full on the one-year anniversary of the grant date (June 5, 2026), indicating a future increase in the director's exercisable equity stake.

Industry Context

This transaction represents a routine equity compensation grant to a director, a common practice across industries, particularly in biotechnology and pharmaceuticals, to attract and retain experienced board members and align their long-term interests with company performance.

Comparison to Industry Standards

• The grant of RSUs and stock options as part of director compensation is a standard practice in publicly traded companies, including those in the biotechnology sector like Amicus Therapeutics.
• The vesting schedule of one year is typical for such grants, aiming to retain directors and incentivize long-term value creation.
• The exercise price of the options ($5.96) is likely tied to the market price of Amicus Therapeutics' stock on the grant date, which is a common method for setting option strike prices.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to Director Margaret G. McGlynn constitutes a related party transaction, which is a standard and disclosed practice for compensating board members.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's interests with shareholder value through equity ownership.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The Restricted Stock Units and stock options granted will vest in full on the one-year anniversary of the grant date (June 5, 2026).

Key Dates

Recommendation

Keywords

Amicus Therapeutics, FOLD, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership